EE76 Budget Impact of Subcutaneous Infliximab in Comparison to Intravenous Infliximab in the Management of Autoimmune Diseases in Greece
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.328
https://www.valueinhealthjournal.com/article/S1098-3015(22)02532-3/fulltext
Title :
EE76 Budget Impact of Subcutaneous Infliximab in Comparison to Intravenous Infliximab in the Management of Autoimmune Diseases in Greece
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02532-3&doi=10.1016/j.jval.2022.09.328
First page :
Section Title :
Open access? :
No
Section Order :
12136